ReviewPsychiatry and clinical psychopharmacology2025
Posttraumatic Stress Disorder Psychopharmacology Algorithm Update-2024-2025.
Review in Psychiatry and clinical psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exercise-induced neuropeptidergic and neurochemical neuroadaptation in stress regulation and emotional disorders.Acta neurologica Belgica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the last publication of the Psychopharmacology Algorithm Project at the Harvard South Shore Program Posttraumatic Stress Disorder (PTSD) algorithm in 2022, additional evidence has reinforced key treatment recommendations. Prazosin remains the first-line treatment for PTSD-related sleep impairment, including nightmares and disturbed awakenings, and it may be useful for individuals with comorbid alcohol use disorder and comorbid headaches. After treating PTSD insomnia, if significant daytime symptoms remain, a selective serotonin reuptake inhibitor ( SSRI, sertraline or paroxetine are suggested), and this may be augmented by an antipsychotic (consider aripiprazole first) if psychotic symptoms, if any, do not respond to the SSRI. If results are still unsatisfactory, a second SSRI or a selective norepinephrine reuptake inhibitor (SNRI) could be considered, though they offer no benefit for hyperarousal symptoms, and prazosin may also be tried for residual daytime symptoms. This update also evaluates emerging treatments, including transcranial magnetic stimulation, direct current stimulation, stellate ganglion block, and pimavanserin, though concluding that current evidence does not yet warrant their inclusion in the core algorithm. This update provides clinicians with an evidenceinformed approach to pharmacological PTSD management based on the latest available data.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.